

TD Asset Management

TD Global Healthcare Leaders Index ETF (TDOC/TDOC.U)

536308
(03/25)

TD Exchange-Traded Funds Annual Management Report of Fund Performance

for the period ended December 31, 2024

This Annual Management Report of Fund Performance contains financial highlights, but does not contain the complete annual financial statements of the investment fund. You can get a copy of the annual financial statements at your request, at no cost, by writing to us at TD Asset Management Inc., P.O. Box 100, 66 Wellington Street West, TD Bank Tower, Toronto-Dominion Centre, Toronto, Ontario, M5K 1G8, or by visiting our website at www.td.com/ca/en/asset-management or the SEDAR+ website at www.sedarplus.ca.



Securityholders may also contact us or visit our website to get a copy of the investment fund's interim financial report, proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure at no cost.

Management Discussion of Fund Performance

Investment Objectives & Strategies

The investment objective of TD Global Healthcare Leaders Index ETF (the "Fund") is to seek to track, to the extent reasonably possible and before the deduction of fees and expenses, the performance of a global equity index which measures the investment return of global issuers related to healthcare. In seeking to achieve this objective, the Fund currently invests in and holds a proportionate share of securities included in the Solactive Global Healthcare Leaders Index (CA NTR). The Fund may also invest in other securities including exchange-traded funds, mutual funds or other public investment funds, American Depositary Receipts or derivative instruments, to obtain exposure to such securities in a manner that is consistent with the investment objective of the Fund.

Risk

The risks of investing in the Fund remain as outlined in the prospectus.

Results of Operations

The Fund is an exchange-traded fund listed on the Toronto Stock Exchange ("TSX"). Units of the Fund are traded under TSX ticker symbol "TDOC" for Canadian dollar denominated units and "TDOC.U" for U.S. dollar denominated units. Units of TDOC returned 9.7% for the year ended December 31, 2024 (the "Reporting Period"), versus 10.1% for the Fund's product benchmark and 29.4% for the Fund's general market index. The Fund's product benchmark is the Solactive Global Healthcare Leaders Index (CA NTR) and its general market index is the MSCI World Index (Net Dividend, C\$). Unlike the product benchmark and general market index, the Fund's return is quoted after the deduction of fees and expenses. Returns for other units of the Fund may vary, largely due to differences in currencies. Refer to the Past Performance section for returns of various units of the Fund.

Market Update

The global economy expanded over the Reporting Period, albeit at a relatively muted pace. Tight financial conditions weighed on consumer demand, hindering trade and business activity. Several major central banks began lowering interest rates in response to softer inflationary pressures and moderating economic conditions. The U.S. economy showed its relative strength, lifted by a resilient U.S. consumer. The U.S. labour market lost some momentum, with the unemployment rate moving higher. With a slower labour market and falling inflation rate, the U.S. Federal Reserve Board lowered its benchmark interest rate by 1.00% to a target range of 4.25%-4.50%. Economic activity in China was relatively stable yet underwhelming, continuing to be negatively impacted by soft domestic demand and a weak property market. China's government provided some fiscal stimulus measures and pledged to provide more in 2025, while the People's Bank of China lowered several interest rates to help support China's economy.

Europe's economy expanded at a relatively modest pace over the Reporting Period. Consumer and business activity continued to be weighed down by tight financial conditions. The European Central Bank lowered interest rates four times, taking its benchmark interest rate to 3.15%. Economic activity in Germany, Europe's largest economy, was weak. Struggles in Germany's key manufacturing sector persisted, which weighed on trade activity and overall economic conditions. In the U.K., the Bank of England lowered its benchmark interest rate from 5.25% to 4.75% in response to falling inflation and relatively weak economic growth. After contracting in the first quarter of 2024, Japan's economy expanded over the second and third quarters, benefiting from higher trade activity. Unlike many other economies, Japan's inflation rate remained elevated, showing little signs of coming down. In response, the Bank of Japan ("BoJ") raised interest rates twice, taking its benchmark interest rate to 0.25%. This was the BoJ's first interest rate increase in 17 years.

Global equity markets posted a strong gain over the Reporting Period. Technology stocks, particularly technology heavyweights in the U.S., drove market performance on strong progress from the development of artificial intelligence capabilities. U.S. equity markets advanced, with 10 of 11 sectors delivering a positive return. Communication services, information technology and consumer discretionary were the strongest-performing sectors, while materials, health care and real estate were the weakest performers.

Chinese equities increased over the Reporting Period, getting a boost from the government's announcement to help support China's economic activity. The financials and information technology sectors drove gains for China's equity markets. European equities posted a relatively solid gain. Financials and industrials were among the top-performing sectors in European equity markets. Among European countries, Italy, Germany and Spain were the top performers. U.K. equities advanced, lifted by gains in the financials and industrials sectors. Japanese equities also gained, benefiting from the strong performance of the financials and energy sectors.

Key Contributors/Detractors Relative to the Product Benchmark

The Fund continues to be managed with the objective of seeking to track the performance of its product benchmark. The Fund's returns are influenced by the same factors that affect the global health care market.

Key Contributors/Detractors Relative to the General Market Index

The Fund's focus on the health care sector was the key reason for its underperformance versus the more diversified general market index. Health care was one of the weakest performing sectors in the MSCI World Index.

Assets

The Fund experienced a significant increase in assets due to investor purchase activity.

Recent Developments

The Portfolio Adviser expects consumer and business activity to pick up after several central banks began to ease monetary policy and loosen financial conditions. Still, several risks to the outlook persist, such as geopolitical tensions, the potential for inflationary pressures to reemerge and the impact of potential tariffs on global trade activity. Many central banks are expected to keep lowering interest rates, which could further boost global economic activity in 2025 and help the global economy avoid a recession. The Portfolio Adviser continues to monitor all the factors that could influence the Fund's investment portfolio.

On April 30, 2024, TD Asset Management Inc. announced that due to an input error, the amount of the distribution declared on March 15, 2024 of \$0.45 per unit of TDOC was higher than the intended distribution of \$0.045 per unit. The higher distribution amount was paid out to unitholders on April 4, 2024. The excess distribution did not result in a net asset value error, though unitholders received a higher distribution than expected. As a result, TD Asset Management Inc. decided to eliminate distributions for units of TDOC for the remaining three quarterly distribution periods as the expected distribution amount for 2024 had already been exceeded. Unitholders can expect a higher portion of the distribution for 2024 to be a return of capital for tax purposes.

Related Party Transactions

Affiliates of TD Asset Management Inc. ("TDAM") may earn fees and spreads in connection with various services provided to, or transactions with, the Fund, such as in connection with banking, deposit-taking, custody, brokerage and derivatives transactions, subject to approval or review by the Fund's independent review committee ("IRC") and/or compliance with applicable internal policies and procedures.

Manager, Trustee and Portfolio Adviser:

TDAM, a wholly-owned subsidiary of The Toronto-Dominion Bank ("TD"), is the manager, trustee, portfolio adviser and promoter of the Fund. Each class of the Fund pays TDAM an annual management fee.

Designated Broker and Dealer:

TDAM has entered into an agreement with TD Securities Inc. ("TDS"), an affiliate of TDAM, to act as designated broker and dealer to perform certain duties for the Fund. The designated broker arrangements entered into with TDS are consistent with market terms and conditions.

Custodian:

TD is the sub-custodian of the Fund and may hold a portion of cash of the Fund.

Buying and Selling Securities:

TDAM has established the IRC to act as an impartial and independent committee to review and provide recommendations or, if appropriate, approvals respecting any conflict of interest matters referred to it by TDAM. The IRC prepares, at least annually, a report of its activities for securityholders of the Fund. The report is available on the TDAM website at www.td.com/ca/en/asset-management or at the securityholder's request at no cost by contacting TDAM (see front cover).

The Fund did not engage in any portfolio transactions requiring IRC approval during the Reporting Period.

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the past five fiscal years, as applicable. For units of the Fund that commenced operations during any of the periods presented, the data reported for that period represents results from the commencement of operations (as disclosed in the Past Performance section) to the end of that reporting period.

Net Assets per Unit (\$)¹

	TDOC (C\$)					TDOC.U (US\$)				
	2024	2023	2022	2021	2020	2024	2023	2022	2021	2020
Net Assets, Beginning of Year	17.19	17.14	17.56	15.00†	N/A	13.00	12.66	13.35†	N/A	N/A
Increase (Decrease) from Operations:										
Total Revenue	0.30	0.30	0.33	0.17	N/A	0.23	0.22	0.19	N/A	N/A
Total Expenses (excluding distributions)	(0.12)	(0.12)	(0.11)	(0.09)	N/A	(0.09)	(0.09)	(0.06)	N/A	N/A
Realized Gains (Losses) for the Period	0.53	0.23	(0.06)	0.26	N/A	0.34	0.18	(0.06)	N/A	N/A
Unrealized Gains (Losses) for the Period	0.69	(0.06)	0.00	1.91	N/A	(0.06)	(0.15)	0.37	N/A	N/A
Total Increase (Decrease) from Operations²	1.40	0.35	0.16	2.25	N/A	0.42	0.16	0.44	N/A	N/A
Distributions:										
From Net Investment Income (excluding dividends)	(0.17)	(0.17)	(0.20)	(0.07)	N/A	(0.10)	(0.17)	(0.10)	N/A	N/A
From Dividends	0.00	0.00	0.00	0.00	N/A	0.00	0.00	0.00	N/A	N/A
From Capital Gains	(0.51)	(0.24)	(0.01)	(0.01)	N/A	(0.13)	(0.27)	(0.01)	N/A	N/A
Return of Capital	0.00	0.00	0.00	(0.04)	N/A	(0.04)	0.00	(0.01)	N/A	N/A
Total Annual Distributions³	(0.68)	(0.41)	(0.21)	(0.12)	N/A	(0.27)	(0.44)	(0.12)	N/A	N/A
Net Assets at December 31	18.40	17.19	17.14	17.56	N/A	12.94	13.00	12.66	N/A	N/A

¹ This information is derived from the Fund's audited annual financial statements prepared in accordance with International Financial Reporting Standards. The Fund measures fair values of its investments based on close market prices, where the close market price falls within the bid-ask spread or based on quotations from recognized dealers. As such, the Fund's accounting policies for measuring the fair value of investments in the financial statements are substantively consistent with those used in measuring the net asset value ("NAV") for transactions with unitholders.

² Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the financial period. This table is not intended to be a reconciliation of the net assets per unit.

³ Distributions were paid in cash or reinvested in additional units of the Fund, or both. The Fund may make notional distributions from time to time and the units issued on reinvestments are immediately consolidated with the units held prior to the notional distribution. As a result, the total number of units held after the notional distribution is identical to the number of units held before the notional distribution. The following table shows the notional distributions for the periods presented, as applicable.

	TDOC (C\$)					TDOC.U (US\$)				
	2024	2023	2022	2021	2020	2024	2023	2022	2021	2020
Notional Income Distribution	0.00	0.00	0.00	0.00	N/A	0.00	0.00	0.00	N/A	N/A
Notional Dividend Distribution	0.00	0.00	0.00	0.00	N/A	0.00	0.00	0.00	N/A	N/A
Notional Capital Gains Distribution	0.23	0.24	0.01	0.01	N/A	0.13	0.27	0.01	N/A	N/A
Notional Return of Capital Distribution	0.00	0.00	0.00	0.00	N/A	0.00	0.00	0.00	N/A	N/A

† Initial offering price.

Ratios and Supplemental Data

	TDOC (C\$)					TDOC.U (US\$)				
	2024	2023	2022	2021	2020	2024	2023	2022	2021	2020
Total Net Asset Value (\$000s)¹	84,628	58,451	30,850	19,316	N/A	2,588	1,300	1,266	N/A	N/A
Number of Units Outstanding (000s)¹	4,600	3,400	1,800	1,100	N/A	200	100	100	N/A	N/A
Management Expense Ratio (%)²	0.39	0.39	0.38	0.38	N/A	0.39	0.40	0.39	N/A	N/A
Management Expense Ratio Before Waivers or Absorptions (%)	0.39	0.39	0.38	0.39	N/A	0.39	0.40	0.40	N/A	N/A
Trading Expense Ratio (%)³	0.03	0.04	0.05	0.17	N/A	0.03	0.04	0.05	N/A	N/A
Portfolio Turnover Rate (%)⁴	25.12	20.13	31.87	31.55	N/A	25.12	20.13	31.87	N/A	N/A
Net Asset Value per Unit (\$)	18.40	17.19	17.14	17.56	N/A	12.94	13.00	12.66	N/A	N/A
Closing Market Price (\$)⁵	18.36	17.30	17.16	17.61	N/A	12.94	13.05	12.69	N/A	N/A

¹ This information is provided as at December 31 of the past five fiscal years, as applicable.

² Management Expense Ratio ("MER") is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) net of any waivers or absorptions for the stated period and is expressed as an annualized percentage of daily average NAV during the period. Any waivers or absorptions may be discontinued at any time by TDAM at its discretion without notice.

³ The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average NAV during the stated period.

⁴ The Fund's portfolio turnover rate ("PTR") indicates how actively the Fund's portfolio adviser manages its investments. A PTR of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the stated period. The higher a fund's PTR, the greater the trading costs payable by the fund in the period, and the greater the chance of an investor receiving taxable capital gains in the fiscal year. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

⁵ Mid price would be used if no transaction took place on the last business day of the financial period.

Management Fees

As manager of the Fund, TDAM is responsible for the overall business and affairs of the Fund, including activities related to providing, or arranging for the provision of, certain administrative services and marketing services to the Fund. In consideration for the provision of such services, the Fund pays TDAM a management fee.

Management fees, plus applicable taxes, are calculated and accrued on a daily basis based on the net asset value of the Fund and are paid monthly to TDAM.

The prospectus discloses a specified annual management fee rate that TDAM can charge to the Fund. TDAM may waive all or a portion of the management fees being charged to the Fund, which may be discontinued at any time by TDAM at its discretion without notice to unitholders.

The annual management fees and a breakdown of the major services rendered, as a percentage of the management fees paid, are as follows:

(expressed as a %)	Annual Mgmt. Fees*	Dealer Compensation	Waived Operating Expenses	Other†
TDOC	0.35	N/A	0.05	99.95
TDOC.U	0.35	N/A	0.03	99.97

* Includes management fees paid by the Fund and the proportionate management fees, if any, of the underlying fund(s) managed by TDAM held by the Fund. However, no management fees are payable by the Fund that, to a reasonable person, would duplicate a fee payable by the underlying fund(s) for the same services.


† Trustee, marketing services and other.

Past Performance


The following charts show how the Fund has performed in the past, and can help you understand the risks of investing in the Fund. These returns include the reinvestment of all distributions during the period in additional units at the net asset value per unit of the Fund at the time of distribution. They do not take into account sales, redemption, distribution or other optional charges or income taxes payable by any unitholder, and these returns would be lower if they did. The Fund's past performance does not necessarily indicate how it will perform in the future.

Year-by-year returns

The bar charts show how the Fund's performance has varied from year to year for each of the years shown. It shows in percentage terms how an investment made on January 1 would have increased or decreased by December 31.



* From April 7, 2021 (commencement of operations) to December 31, 2021



* From March 29, 2022 (commencement of operations) to December 31, 2022

Annual Compound Returns

The following table shows the annual compound total returns of the Fund for each of the periods indicated ended on December 31, 2024, compared with the following benchmarks:

- Product Benchmark:
 - Solactive Global Healthcare Leaders Index (CA NTR) – This index intends to track the performance of securities of global large and mid-capitalization issuers that are related to healthcare, net of withholding taxes.
- General Market Index:
 - MSCI World Index (Net Dividend) – This index includes stocks of companies in all the developed markets around the world, net of withholding taxes.

(expressed as a %)	Past year	Past 3 years	Past 5 years	Past 10 years	Since inception
TDOC (C\$) (Apr. 7, 2021)	9.7	3.1	N/A	N/A	7.1
Product Benchmark (C\$)	10.1	3.6	N/A	N/A	7.6
General Market Index (C\$)	29.4	11.0	N/A	N/A	12.5
TDOC.U (US\$) (Mar. 29, 2022)	0.5	N/A	N/A	N/A	0.0
Product Benchmark (US\$)	1.0	N/A	N/A	N/A	0.5
General Market Index (US\$)	18.7	N/A	N/A	N/A	8.3

A discussion of the Fund's performance compared to the product benchmark and general market index can be found in the Results of Operations section.

Summary of Investment Portfolio

as at December 31, 2024

	% of Net Asset Value
PORTFOLIO ALLOCATION	
Pharmaceuticals	31.4
Health Care Equipment & Supplies	26.6
Biotechnology	15.0
Health Care Providers & Services	14.3
Life Sciences Tools & Services	10.3
Health Care Technology	1.0
Personal Care Products	0.9
Cash (Bank Overdraft)	0.2
Electronic Equipment, Instruments & Components	0.2
Other Net Assets (Liabilities)	0.1
GEOGRAPHIC ALLOCATION	
United States	64.2
Japan	8.1
Switzerland	6.5
United Kingdom	5.1
Australia	2.8
Ireland	2.4
Germany	2.4
Denmark	2.3
France	2.0
Netherlands	1.4
Other Countries	2.5
Cash (Bank Overdraft)	0.2
Other Net Assets (Liabilities)	0.1
TOTAL NET ASSET VALUE (000s)	\$ 88,350

	% of Net Asset Value
TOP 25 INVESTMENTS	
Gilead Sciences Inc.	2.4
Bristol-Myers Squibb Company	2.4
Intuitive Surgical Inc.	2.3
Boston Scientific Corporation	2.3
Stryker Corporation	2.2
Abbott Laboratories	2.1
AbbVie Inc.	2.0
Roche Holding AG	2.0
Medtronic PLC	2.0
Merck & Company Inc.	2.0
Johnson & Johnson	2.0
CSL Limited	1.9
McKesson Corporation	1.9
Pfizer Inc.	1.9
Sanofi SA	1.9
Thermo Fisher Scientific Inc.	1.9
Vertex Pharmaceuticals Inc.	1.9
Zoetis Inc.	1.9
UnitedHealth Group Inc.	1.9
AstraZeneca PLC	1.9
Danaher Corporation	1.9
Novartis AG	1.9
Eli Lilly & Company	1.9
GSK PLC	1.8
Amgen Inc.	1.8
Total % of Net Asset Value represented by these holdings	50.1

Note: Totals may not add due to rounding to one decimal place of individual figures.

The Fund is not sponsored, promoted, sold or supported in any other manner by Solactive AG nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Solactive Global Healthcare Leaders Index (CA NTR) (the "Index") and/or any trade mark(s) associated with the Index or the price of the Index at any time or in any other respect. The Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards TDAM, Solactive AG has no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the Fund. Neither publication of the Index by Solactive AG nor the licensing of the Index or any trade mark(s) associated with the Index for the purpose of use in connection with the Fund constitutes a recommendation by Solactive AG to invest capital in said Fund nor does it in any way represent an assurance or opinion of Solactive AG with regard to any investment in the Fund.

The Summary of Investment Portfolio may change due to ongoing portfolio transactions of the Fund. Updates are available quarterly. You may obtain the most current quarterly information by writing to us at TD Asset Management Inc., P.O. Box 100, 66 Wellington Street West, TD Bank Tower, Toronto, Ontario, M5K 1G8, or by visiting our website at www.td.com/ca/en/asset-management.

Caution regarding forward-looking statements

Certain portions of this report, including, but not limited to, “Results of Operations” and “Recent Developments”, may contain forward-looking statements including, but not limited to, statements about the Fund, its strategy, risks, expected performance and condition. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar forward-looking expressions or negative versions thereof.

In addition, any statement that may be made concerning future performance, strategies or prospects, and possible future Fund action, is also a forward-looking statement. Forward-looking statements are based on current expectations and projections about future general economic, political and relevant market factors, such as interest rates, foreign exchange rates, equity and capital markets, and the general business environment, in each case assuming no changes to applicable tax or other laws or government regulation. Expectations and projections about future events are inherently subject to, among other things, risks and uncertainties, some of which may be unforeseeable. Accordingly, assumptions concerning future economic and other factors may prove to be incorrect at a future date.

Forward-looking statements are not guarantees of future performance, and actual events could differ materially from those expressed or implied in any forward-looking statements made by the Fund. Any number of important factors could contribute to these digressions, including, but not limited to, general economic, political and relevant market factors in North America and internationally, interest and foreign exchange rates, equity and capital markets, business competition, technological change, changes in government relations, unexpected judicial or regulatory proceedings and catastrophic events.

The above mentioned list of important factors is not exhaustive. You are encouraged to consider these and other factors carefully before making any investment decisions and you are urged to avoid placing any undue reliance on forward-looking statements. Further, there is no specific intention of updating any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

Source: London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2024. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®”, “Russell®”, and “FTSE Russell®” are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

TD Exchange-Traded Funds are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank.

Epoch Investment Partners, Inc. operates in the United States and is an affiliate of TD Asset Management Inc. TD Asset Management Inc. operates in Canada. Both are wholly-owned subsidiaries of The Toronto-Dominion Bank.

®The TD logo and other TD trademarks are the property of The Toronto-Dominion Bank or its subsidiaries.